In Re Application of: Ikunoshia KATO et al,

Application No.: 09/937,375 Filed: September 24, 2001

**GENE THERAPEUTICS** 

NEHE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: 1635

Examiner: J. Angell

Washington, D.C.

Atty.'s Docket: KATO=18

Date: September 29, 2005 Confirmation No. 8012

OR

OR

THE COMMISSIONER OF PATENTS U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Sir:

Transmitted herewith is a [XX] REPLY: AMENDMENT AND REMARKS in the above-identified application.

[ ] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

No additional fee is required. [XX]

The fee has been calculated as shown below:

(Col. 1)					(Col. 2)	(Col. 3)			
	CLAIMS REMAINING AFTER AMENDMENT			PRI	HEST NO. EVIOUSLY AID FOR	PRESENT EXTRA EQUALS			
TOTAL	•	3	MINUS	*	20	0			
INDEP.	*	1	MINUS	***	3	0			
FIRST PRESENTATION OF MULTIPLE DEPLOYAM									

	SMALL ENTITY				
	RATE	ADDITIONAL FEE			
	x 25	\$			
	x 100	\$			
	+ 180	\$			
ADDITIO	NAL FEE TOTA	L \$			

OTHER THAN SMALL ENTITY RATE **ADDITIONAL** FEE 50 \$ 200 S 360 TOTAL

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time [XX]

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

		Small Entity		o	ther	Than Small	Ent	ity		
		Response Filed Within		R	espo	nse Filed W	'ithi	n		
		[ ] First - \$ 60.00		[	]	First	-	\$	120.00	
		[ ] Second - \$ 225.00		[	]	Second	-	\$	450.00	
		[ ] Third - \$ 510.00		[	}	Third	-	\$	1020.00	
		[ ] Fourth - \$ 795.00		[	]	Fourth	-	\$	1590.00	
		Month After Time Period Set		Month After Time Period Set						
]	1	[ ] Less fees (\$) already paid for month(s) extension of  Please charge my Deposit Account No. 02-4035 in the amount of \$	•							
]	1	Credit Card Payment Form, PTO-2038, is attached, authorizing payment	nt in the ar	mo	ount o	of \$				
Į.	]	A check in the amount of \$ is attached (check no. ).								

The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

egistration No. 25,884

Facsimile:

(202) 737-3528 Telephone: (202) 628-5197



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	ATTY.'S DOCKET: KATO=18
In re Application of:	) Art Unit: 1635 )
Ikunoshin KATO et al	) Examiner: J. E. Angell
I.A. Appln. PCT/JP00/01533 I.A. Filing Date: 3/14/2000	) Washington, D.C. )
U.S. Appln. No. 09/937,375 Nationalized: 9/24/2001	) Confirmation No. 8012 )
For: GENE THERAPEUTICS	) September 29, 2005

## REPLY: AMENDMENT AND REMARKS

Customer Service Window, Mail Stop Amendment Honorable Commissioner for Patents U.S. Patent and Trademark Office Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

Replying to the Office Action mailed July 6, 2005, please amend as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.